+++
title = 'Suven Pharmaceuticals Ltd:Annual Report 2023-24 Analysis'
date = 2024-07-16 21:18:07
readTime = true
tags = ["Suven Pharmaceuticals Ltd.", "SUVENPHAR", "Pharmaceuticals - Diversified", "Healthcare","Mid Cap", "Annual Report", "2023-24"]
showTags = true
toc = true
+++

## Suven Pharmaceuticals Ltd: A Comprehensive Overview

### About the Company

**Year of Establishment and Founding History:** Suven Pharmaceuticals Ltd. was established in 2003 as a spin-off from Suven Life Sciences Limited.

**Headquarters Location and Global Presence:** The company is headquartered in Hyderabad, India. They operate globally, with a strong presence in North America, Europe, and Asia.

**Company Vision and Mission:** While a specific publicly declared vision and mission statement are not readily available, Suven Pharmaceuticals focuses on being a premier contract development and manufacturing organization (CDMO) and API supplier, providing high-quality and cost-effective solutions to global pharmaceutical companies.

**Key Milestones in their Growth Journey:**

*   **2003:** Spin-off from Suven Life Sciences Limited.
*   **Expansion of CDMO capabilities:** Significant investments in expanding manufacturing infrastructure and R&D capabilities.
*   **Strategic Acquisitions:** Acquisition of Casper Pharma further solidifying presence in the CDMO space.

**Stock Exchange Listing Details and Market Capitalization:** Suven Pharmaceuticals is listed on the Bombay Stock Exchange (BSE: 543064) and the National Stock Exchange (NSE: SUVENPHAR). The market capitalization fluctuates with market conditions; please refer to financial websites for the most up-to-date information.

**Recent Financial Performance Highlights:** (Please refer to the company's official financial reports and investor presentations for the most current data.)

**Management Team and Leadership Structure:** The company is led by a team of experienced professionals in the pharmaceutical industry. Key leadership typically includes:

*   **Managing Director/CEO:** Driving overall strategy and operations.
*   **Chief Financial Officer (CFO):** Overseeing financial management.
*   **Chief Operating Officer (COO):** Managing day-to-day operations.

**Any Notable Awards or Recognitions:** Suven Pharmaceuticals has received awards and recognition for its quality, safety, and sustainability practices. (Please refer to the company's website or press releases for details.)

### Their Products

**Complete Product Portfolio with Categories:** Suven Pharmaceuticals operates primarily in two segments:

*   **Contract Development and Manufacturing Organization (CDMO):** Providing custom synthesis, process development, scale-up, and manufacturing services to pharmaceutical companies.
*   **Active Pharmaceutical Ingredients (APIs):** Manufacturing and supplying APIs for various therapeutic areas.

**Flagship or Signature Product Lines:** The company specializes in niche APIs and advanced intermediates. Specific flagship products are often confidential due to client relationships.

**Key Technological Innovations or Patents:** Suven focuses on developing innovative manufacturing processes for APIs and intermediates. The number of patents filed/granted would require further company-specific research.

**Manufacturing Facilities and Production Capacity:** The company has multiple manufacturing facilities in India, equipped with advanced technology and infrastructure. Production capacity details are not readily available publicly and are competitively sensitive.

**Quality Certifications and Standards:** Suven Pharmaceuticals adheres to stringent quality standards and holds certifications such as:

*   US FDA
*   European GMP (Good Manufacturing Practice)
*   Other relevant regulatory approvals.

**Any Unique Selling Propositions or Technological Advantages:**

*   **Strong focus on niche APIs and intermediates:** Allowing for high-value products.
*   **Integrated CDMO services:** Providing end-to-end solutions to pharmaceutical clients.
*   **Strong R&D capabilities:** Enabling the development of innovative manufacturing processes.

### Primary Customers

**Target Industries and Sectors:** The primary target industry is the global pharmaceutical industry.

**Geographic Markets (domestic vs. international):** Primarily international markets, including North America, Europe, and Asia.

**Major Client Segments:** Pharmaceutical companies requiring CDMO services and APIs.

**Distribution Network and Sales Channels:** Direct sales and marketing to pharmaceutical companies.

### Major Competitors

**Direct Competitors in India and Globally:**

*   **In India:** Divis Laboratories, Laurus Labs, Syngene International.
*   **Globally:** Lonza, Catalent, Thermo Fisher Scientific (for CDMO services).

**Competitive Advantages and Disadvantages:**

*   **Advantages:** Strong R&D capabilities, focus on niche APIs, integrated CDMO services.
*   **Disadvantages:** Subject to market volatility and regulatory changes, intense competition in the CDMO space.

**How they differentiate from competitors:** Focus on niche products, strong client relationships, and a commitment to quality and innovation.

### Future Outlook

**Expansion Plans or Growth Strategy:** Suven Pharmaceuticals aims to expand its manufacturing capacity, strengthen its R&D capabilities, and expand its geographic reach through organic growth and strategic acquisitions.

**Upcoming Products or Innovations:** Focus on developing new APIs and innovative manufacturing processes.

**Sustainability Initiatives or ESG Commitments:** Suven Pharmaceuticals is increasingly focusing on sustainability initiatives and ESG (Environmental, Social, and Governance) commitments. (Specific details on these commitments should be sought from the company's official communications.)

**Industry Trends Affecting their Business:**

*   **Increasing demand for CDMO services:** Driven by pharmaceutical companies focusing on core competencies.
*   **Growing demand for APIs:** Driven by the growth of the pharmaceutical industry.
*   **Increasing regulatory scrutiny:** Requiring companies to adhere to stringent quality standards.

**Long-term Vision and Strategic Goals:** To be a leading global CDMO and API supplier, providing innovative and high-quality solutions to the pharmaceutical industry.

---
## Suven Pharmaceuticals Limited: Financial Analysis

### 3-Year Trend Analysis of Key Financial Metrics

*   **Revenue:** Consolidated revenue decreased by 21.6% in FY24 (₹1,051.35 crore) compared to FY23 (₹1,340.33 crore), and adjusted for the COVID base and Agro chemical destocking cycle, the business grew at 16.2% in FY24. The Pharma segment, adjusted for the COVID base, grew at 9.4%.
*   **EBITDA:** Consolidated EBITDA decreased from ₹587.6 crore in FY23 to ₹435 crore in FY24. Adjusted EBITDA margins for FY24 stood at 41.4% (43.8% in FY23), after one-time adjustments of ₹211 crore.
*   **Profitability:** Consolidated Profit for the Year decreased from ₹411.29 crore in FY23 to ₹300.28 crore in FY24. The Adjusted PAT margin, was reported as 30.4%.
*   **Debt Equity Ratio:** Improved to 0.02 in FY24 from 0.04 in FY23, due to decreased borrowings.
*   **Current Ratio:** Increased to 11.47 in FY24 from 6.19 in FY23, due to increased investments and decreased current liabilities.
*   **Operating Profit Margin**: decreased to 35.23% in FY24, compared to 40.62% due to decrese in revenue.

### Business Segment Performance

*   **Pharma CDMO:** The Pharma segment adjusting for the COVID base, grew at 9.4%. The company is targeting to double the sales of its Pharma CDMO business over the next five years. The number of intermediates in Phase III increased from 6 to 13, and molecules in Phase III increased from 2 to 7. RFQs and conversions have more than doubled compared to previous years.
*   **Specialty Chemicals CDMO:** Reframed as a new strategic business unit with increased investment in domain experts and infrastructure. The company anticipates trend reversal in growth from Q2 FY25.
*   **API++ (Cohance Lifesciences):** Expects double digit growth through market share expansion and new product validations.

### Major Strategic Initiatives and Their Progress

*   **Customer Engagement:** Increased customer engagement resulted in a significant increase in RFQs, with conversion rates more than doubling.
*   **Cost Optimization:** Over 30 implementable cost-saving ideas from the shop/floor team, contributing to expense optimization.
*   **Infrastructure Upgrades:** Completed an FDA audit with Zero 483 observations at the Pashamylaram facility. Inaugurated a new R&D facility in Genome Valley. The new block in Suryapet is undergoing validations and is on track for commissioning.
*   **Merger with Cohance Lifesciences:** The merger is progressing, with approvals received from NSE and BSE. The expected timeline for completion is 12-15 months from February 29, 2024. The merger is expected to accelerate growth momentum and expand capabilities.
*   **Acquisition of Sapala Organics Private Limited:** pending statutory approvals, your company plans an initial acquisition of a 67.5% equity stake, which aims to boost the companies capabilities.

### Risk Landscape Changes

*   **Geopolitical Risks:** Global players seeking to de-risk supply chains from China (China+1 strategy) present opportunities for Indian CDMOs. The USA's Biosecure Act potentially creates further opportunities.
*   **European Cost Pressures:** High manufacturing costs in Europe are driving enterprises to shift their sourcing base towards Asia, particularly India.
*   **Dependence on Imports**:Reliance on imports for KSM and APIs can affect delivery schedule.
*   **Client and Molecule Concentration**: Reliance on select client and a limited number of key molecules.

### ESG Initiatives and Metrics

*   **EHS Awards:** Pashamylaram Unit 3 received the EHS Excellence Award by the CII. The Pashamylaram facility also received the International Safety Award from the British Safety Council.
*   **CSR Spending:** ₹778.12 lakhs spent on social and environmental commitments in 2023-24. Focus areas include education, healthcare, women empowerment, environmental sustainability, rural development, and safe drinking water.

### Management Outlook

*   **FY25 Outlook:** Positive outlook for FY25, with expected growth in revenue and EBITDA, driven by an increase in the clinical pipeline and China Plus One dynamics. Recovery is expected in H2 FY25.
*   **Mid-Term to Long-Term Growth:** The Company anticipates accelerated growth, supported by favourable industry conditions and increased inquiries for commercial molecules under patent.
*   **Cohance Merger impact**: At a combined platform level, expected to organically double the business over the next /five years and adding further growth traction from M&A opportunities.

---
#### Detailed Analysis
---
## Financial Position Analysis of Suven Pharmaceuticals Limited

### Balance Sheet - 3-Year Comparative Analysis (Consolidated, in C Lakhs)

| Item                            | March 31, 2024 | March 31, 2023 | March 31, 2022 |
| :------------------------------ |---------------:|---------------:|---------------:|
| **Assets**                      |                |                |                |
| Non-Current Assets             |      99,090.02 |       95,469.80 |  95,097.86     |
| Current Assets                 |   1,26,318.63   |    1,01,104.58 |    94,381.58    |
| **Total Assets**              | **2,25,408.65**| **1,96,574.38**|   **1,89,479.44**              |
| **Equity**                      |                |                |                |
| Equity Share Capital           |       2,545.65 |       2,545.65 |            2,545.65 |
| Other Equity                   |   2,02,520.70  |    1,70,972.78 |   1,47,626.74       |
| **Total Equity**                | **2,05,066.35**|**1,73,518.43**|        **1,50,172.39**       |
| **Liabilities**                 |                |                |                |
| Non-Current Liabilities        |       9,652.73 |       7,179.37 |        5,725.22    |
| Current Liabilities             |      10,689.57 |     15,876.59 |           33,581.83 |
| **Total Liabilities**         |  **20,342.30**     |   **23,055.95**         |    **39,307.05**        |

### Significant Year-over-Year Changes (>10%)

*   **Current Assets (FY24 vs. FY23):** Increased by 24.93%, primarily due to the increase of investment in mutual funds by 80%.
*   **Total Equity (FY24 vs. FY23):** Increased by 18.18% which increased from retained earning.
*   **Current Liabilities (FY24 vs. FY23):** Decreased by 32.67%, mainly because of the decrease of trade payable.

### Working Capital Trends

| Metric               | March 31, 2024    | March 31, 2023  |
|----------------------|-------------------|------------------|
| Current Assets        | 1,26,318.63         |   1,01,104.58          |
| Current Liabilities   |   10,689.57               |  15,876.59                |
| Working Capital      | 1,15,629.06            |   85,227.99            |
| Current Ratio      | 11.82|        6.37      |

*Working capital increased significantly, driven by growth in current investments. The current ratio has drastically improved, indicating enhanced short-term solvency.*

### Debt Structure and Maturity Profile

| Debt Type                        | March 31, 2024 | March 31, 2023 |
| :------------------------------- |---------------:|---------------:|
| Non-Current Borrowings          |              - |         456.42 |
| Current Borrowings (Short-term) |       3,857.53 |       6,459.78 |
| Lease Liabilities                |2,642.11         |            117.88         |

*Current portion of long-term debt significantly reduced.*

### Off-Balance Sheet Items

*   **Contingent Liabilities:** C 1,585.23 lakhs as of March 31, 2024, related to APIIC-JN Pharmacity restoration fees and disputes with indirect taxes.
*  **Commitments:** C 4,044.73 committed for exectution of capital contracts.

## Operating Performance Analysis of Suven Pharmaceuticals (FY24)

### Revenue Breakdown

*   Consolidated Revenue (FY24 vs. FY23): Declined by 21.6% from ₹1,34,033 lakhs to ₹1,05,135 lakhs. The Pharma segment, adjusted for the COVID base, grew at 9.4%.
*   Standalone Revenue: Decreased by 23% from ₹1,33,008 Lakhs (FY23) to ₹1,02,499 Lakhs (FY24).
*   Exports: Constituted 89.79% of total revenue from operations, amounting to ₹92,034 lakhs in FY24.

#### Geographic Revenue Breakdown (₹ in Lakhs)

| Region          | FY24       | FY23       |
|-----------------|------------|------------|
| Europe          | 73,622.83  | 1,16,177.39|
| North America   | 15,025.86  | 8,339.01   |
| India           | 9,392.17   | 2,593.35   |
| Rest of World   | 5,543.79   | 6,001.26   |
| Related Party   | 492.93     | 614.27     |

### Cost Structure Analysis (Standalone)

*   Cost of Materials Consumed: Decreased from ₹42,136.24 lakhs (FY23) to ₹24,838.44 lakhs (FY24).
*   Employee Benefit Expenses: Increased from ₹10,858.10 lakhs (FY23) to ₹12,687.84 lakhs (FY24).
*   Manufacturing expenses: Decreased from ₹17,164.59(FY23) to ₹12,777.79 (FY24).

### Margin Analysis (Consolidated)

*   Reported EBITDA Margin (FY24): 39.4%.
*   Adjusted EBITDA Margin (FY24): 41.4% (adjusting for one-time costs of ₹769 lakhs, including ESOP charge and expenses for the proposed merger).
*   Adjusted EBITDA Margins (FY23): 43.8%.
*   Adjusted PAT Margin (FY24): 30.4%.

#### Standalone Margin Analysis

*   Operating Profit Margin: 35.23% (FY24) vs. 40.62% (FY23)
*   Net Profit Margin: 28% (FY24) vs. 33% (FY23)

### Non-Recurring Items (Consolidated)

*   FY24 One-Time Costs: ₹769 lakhs, comprising an ESOP charge of ₹199 lakhs and ₹570 lakhs related to the proposed merger of Cohance Lifesciences.

### GAAP vs. Non-GAAP Reconciliation

*   Adjusted EBITDA provided with exclusion for one-time costs.

### EPS Analysis (Consolidated)

*   Basic EPS: Decreased from ₹16.16 (FY23) to ₹11.80 (FY24).
*   Diluted EPS: Decreased from ₹16.16 (FY23) to ₹11.80 (FY24).

## Cash Management: Suven Pharmaceuticals Financial Analysis

### Cash Flow and Liquidity Analysis

#### OCF, ICF Components (Consolidated)

*   **OCF:** FY24: ₹358.48 crore, down from ₹492.82 crore in FY23. Decrease driven by lower profit before tax. Operating profit before working capital changes was ₹413.12 crore, down from ₹572.54 crore.
*   **ICF:** FY24: ₹(362.25) crore, decreased from ₹(195.01) crore in FY23. Driven by purchase of property, plant and equipment and sale/(purchase) of mutual funds.

#### Working Capital Management Efficiency (Consolidated)

*   Inventory turnover days: 74 in FY24 vs 86 in FY23.
*   Debtor turnover days: 43 in FY24 vs 30 in FY23.

#### Capex Analysis

*   Total Property, Plant and Equipment additions (capitalized) during FY24 were ₹7,765.36 lakhs (Standalone) and ₹8,276.06 lakhs (Consolidated).

#### Dividend and Share Buyback Trends

*   No dividends paid or proposed in FY24. Previous period dividend was ₹203.65 crore.
*   No share buyback information available.

#### Debt Service Coverage (Consolidated)

*   Debt Service Coverage Ratio: 8.67 in FY24, down from 12.05 in FY23.
*   Interest Coverage Ratio: 62.61 times in FY24, up from 49.83 in FY23 due to decreased borrowing costs.

#### Liquidity Position (Consolidated)

*   Current Ratio: 11.47 in FY24, increased from 6.19 in FY23.

## Financial Analysis: Key Performance Indicators

### Profitability Ratios (3-Year Trends)

*   **Return on Equity (ROE):** FY24: 16%, FY23: 26%. A significant decrease is observed, indicating reduced profitability relative to shareholders' equity.
*   **Operating Profit Margin:** FY24: 35.23%, FY23: 40.62%. The operating margin decreased, indicating lower profitability.
*   **Net Profit Margin:** FY24: 28% , FY23: 33%. The net profit margin has decreased, suggesting reduced efficiency in converting revenue to profit.

### Liquidity Metrics

*   **Current Ratio:** FY24: 11.47, FY23: 6.19. The Group's current ratio is very high and increased substantially, indicating strong short-term solvency, far exceeding standard benchmarks.

### Efficiency Ratios

*   **Inventory Turnover Ratio (Days):** FY24: 74 days, FY23: 86 days. Inventory turnover improved in FY24, requiring fewer days to convert, but it still suggest slow moving.
*   **Debtor Turnover Ratio (Days):** FY24: 43 days, FY23: 30 days. The debtor turnover period increased, indicating slower collection from customers.

### Leverage Metrics

*   **Debt-Equity Ratio:** FY24: 0.02, FY23: 0.04. The Group has very low leverage, with minimal debt compared to equity and improved slightly.
*   **Interest Coverage Ratio:** FY24: 62.61, FY23: 49.83. The very high-interest coverage ratio improved, demonstrating the Group's strong ability to meet interest obligations, exceeding the industry by large numbers.

### Working Capital Ratios

*   **Working Capital Ratio:** The working capital of the Group has seen a decrease when revenue and profitability are decreasing.

### Comparison with Industry Averages and Significant Deviations

*   **Profitability:** The decrease in profitability ratios (ROE, and Profit margins) is significant despite still holding high numbers.
*   **Liquidity:** The extremely high current ratio suggests a potential over-investment in current assets or under-utilization of available capital.
*   **Efficiency:** The increase in debtor turnover days needs to be addressed.
*   **Leverage:** Very low debt/equity ratio indicates the Group is financing its operations largely through equity.
* The company generated a postive cash flow from operations for the FY24.

## Suven Pharmaceuticals Limited: Financial Analysis (FY24)

### Segment Performance Analysis

#### Revenue and Profitability Metrics with Growth Rates

*   Overall Revenue: Declined by 21.6% (Consolidated, FY24 vs. FY23), from ₹1,340.33 crore to ₹1,051.35 crore. Standalone revenue decreased by 23%.
*   Pharma CDMO (ex-COVID base): Grew by 9.4% in FY24.
*   Adjusting for COVID base and Agro Chemical destocking cycle: the business grew by 16.2% on a consolidated Basis in FY24.
*   EBITDA: Decreased from ₹587.6 crore (FY23) to ₹435 crore (FY24) on a consolidated basis.
*   Reported EBITDA Margin (Consolidated): 39.4% (FY24), a decrease from the previous year.
*   Adjusted EBITDA Margin (Consolidated, excluding one-time costs): 41.4% (FY24), was stated as 43.8% for FY23.
*   Profit for the Year (Consolidated): Decreased from ₹411.29 crore (FY23) to ₹300.28 crore (FY24).
*   Net Profit Margin: Slipped to 28% compared to 33% the previous year.

#### Market Share and Competitive Position

*   The company aims to become a Tier-1 supplier to its top 5 customers.
*   The Company is growing its customer base and served more than 30 innovator companies in the last 5 years.

#### Key Products/Services Performance

*   **Pharma CDMO:** Witnessed a significant increase in RFQs, with conversions more than doubling compared to previous years. Phase III intermediates increased from 6 to 13, and Phase III molecules increased from 2 to 7 (FY23 vs. FY24).
*   **Specialty Chemicals CDMO:** Remodeled as a new strategic business unit.
*   **Cohance Lifesciences (Merger Target):** ADC platform is growing significantly; Non-ADC CDMO has one product progressing well in Phase 3; API plus business is expected to return to healthy growth rates. 5 new product validations by Cohance were completed by March 2024.

#### Geographic Distribution and Market Penetration

*   Exports: Accounted for 89.79% of total revenue from operations (₹92,034 lakhs out of ₹1,02,499 lakhs) in FY24.
*   Key Markets: USA and Europe are the largest markets, while Asia Pacific is the second largest.
*   The company has a physical presence and operations in: India (multiple locations), and the USA (New Jersey).

#### Segment-wise CAPEX and ROIC

*   New R&D Facility: The company has set up a new 25,000 Sq.Ft R&D Facility.
*   R&D expenditure: It increased from Rs. 8.59 Crores to 16.12 Crore.

#### Operational Efficiency Metrics

*   Cost Optimization: Over 30 implementable cost-saving ideas generated from the shop floor team.
*   Inventory Turnover Ratio: at 74 days from 86 days.
*   Debtor Turnover Ratio: Increased to 43 days, decreased from 30 days, indicating a slower collection cycle.

#### Growth Initiatives and Challenges

*   **Growth Initiatives:**
    *   Scaling and deepening existing customer relationships, aiming to become a Tier-1 supplier.
    *   Scaling up developmental revenues and investing in infrastructure.
    *   Moving up the value chain from intermediates to API levels.
    *   Building a winning lateral business by farming existing customers.
    *   Incubating/acquiring select new technologies (e.g., flow chemistry, oligonucleotides).
    *   Merger with Cohance Lifesciences to expand capabilities and accelerate growth.
    *   Acquiring Sapala Organics to expand technological capabilities.
*   **Challenges:**
    *   Reliance on imports for Key Starting Materials (KSM) and APIs.
    *   A significant portion of the business relies on a select clientele and a limited number of key molecules.
    *   Price competition from generic players.
    *   Reliance on innovator molecules progressing to subsequent phases of clinical development.
    *   FY24 was impacted by a global slowdown, Agro-Chemical destocking, COVID base effect, and commodity pricing.

## Suven Pharmaceuticals Limited - Segment-Wise Risk Analysis (FY2023-24 vs. FY2022-23)

The provided document combined all operations into a single reportable segment that manufactures NCE-based intermediates, API's, specialty chemicals and formulations.

## Strategic Risks

*   **Severity:** High. Reliance on innovator molecules progressing to subsequent phases of clinical development and reliance on key clients are sources for material revenue loss.
*   **Likelihood:** Medium. The pharmaceutical industry faces challenges, including late-stage asset failures.
*   **Trend:** Increasing. The clinical pipeline growth and China Plus One dynamics are increasing RFQs, potentially exacerbating reliance on key clients and molecules. Phase III intermediates increased from 6 to 13, and molecules from 2 to 7.
*   **Mitigation Strategies:** Scale and deepen existing relationships, scale up developmental revenues, move up the value chain. Build and deploy key account management.
*   **Control Effectiveness:** Partially Effective. Increase in RFQs and conversion rates indicate some success, yet the core risks remain.
*   **Potential Financial Impact:** Significant revenue decline if key molecules fail or key customer relationships are impacted. FY24 saw a revenue decline of 21.6% (Consolidated).

## Operational Risks

*   **Severity:** Medium to High. Reliance on imports for Key Starting Materials (KSM) and Active Pharmaceutical Ingredients (APIs).
*   **Likelihood:** Medium. Supply chain disruptions are mentioned as an industry headwind.
*   **Trend:** Stable. The company recognizes the risk.
*   **Mitigation Strategies:** Cost optimization strategies, supplier risk mitigation, and minimizing China dependence. Implemented 30+ cost-saving ideas.
*   **Control Effectiveness:** Partially effective. Cost-saving measures and FDA audit clearances indicate operational controls, but import reliance remains.
*   **Potential Financial Impact:** Delivery schedule delays.

## Financial Risks

*   **Severity:** Medium to High.
*   **Likelihood:** Medium. Fluctuations in revenue and profitability.
*   **Trend:** Increasing. The company reported a decrease in EBITDA (from C 587.6 crore in FY23 to C 435 crore in FY24) and Profit for the Year (from C 411.29 crore to C 300.28 crore).
*   **Mitigation Strategies:** Cost optimization and supplier risk mitigation.
*   **Control Effectiveness:** Partially effective. EBITDA margins are being maintained, but overall profitability has decreased.
*   **Potential Financial Impact:**
    * Debt Service Coverage Ratio decreased by 28%.
    * Debtor Turnover Ratio (days) increased by 42%.
    * Operating Profit Margin (%) decreased by 13%.
    * Net Profit Margin (%) decreased by 14%.

## Compliance/Regulatory Risks

*   **Severity:** High. Any non-compliance with regulations could result in penalties and reputational damage.
*   **Likelihood:** Low. The Company achieved USFDA audit clearance with Zero 483 observations, indicating strong compliance.
*   **Trend:** Stable.
*   **Mitigation Strategies:** Maintained EHS management and quality management systems.
*   **Control Effectiveness:** High, as evidenced by successful audit outcomes.
*   **Potential Financial Impact:** Not quantifiable from the provided data, but regulatory failures typically result in /fines and operational restrictions.

## Emerging Risks

### Geopolitical Risks
*   Severity: Medium to High.
*   Likelihood: Increasing. Geopolitical instability and supply chain issues were mentioned.
*   Trend: Increasing. The document mentions the USA's Biosecure Act impacting Chinese biotechnology firms, creating both opportunities and risks for Indian CDMOs.
*   Mitigation Strategies: Diversifying supply chains (China +1 strategy).
*   Control Effectiveness: The documents do not provide enough information to judge.
*   Potential Financial Impact: Not quantifiable, but potential supply chain disruptions and increased costs.

### Agrochemical Sector Risks
*   Severity: Medium to high.
*   Likelihood: Medium.
*   Trend: Unclear
*   Mitigation Strategies: The documents show a new strategic unit for specialty chemical.
*   Control Effectiveness: Not accessed in the documents.
*   Potential Financial Impact: 10-12% price decline and 5-7% volume decline in 2023.

## Strategic and Management Analysis of Suven Pharmaceuticals

### Long-Term Strategic Goals and Progress

*   **Goal:** To double the sales of its Pharma CDMO business over the next five years while maintaining industry-leading EBITDA margins.
*   **Goal:** To become India's most admired CDMO company by 2029.
*   **Progress:** Operational progress in FY24 with enhanced customer engagement, including a 25% increase in RFQs, a higher win rate, and positive discussions with major innovator companies.
*   **Progress:** Pipeline movement to Phase 3, doubled from 2 molecules to 7 molecules.
*   **Goal:** Build or acquire new technology in areas including flow chemistry and oligonucleotides.
*   **Progress:** Scouting for technology platforms, referencing Sapala Organics as a target.

### Competitive Advantages and Market Positioning

*   **Advantage:** Pure-play CDMO, focusing on custom synthesis, process R&D, scale-up, and contract manufacturing.
*   **Advantage:** Possesses a large repository of chemistry skills, specializing in cyanation, heterocyclic, carbohydrate, and chiral chemistry.
*   **Advantage:** Experience working with top global innovator companies.
*   **Advantage:** Demonstrated on-time delivery track record (over 900 CDMO projects).
*   **Positioning:** Shifting from a domestic CDMO player to a global CDMO partner-of-choice.
*   **Market Positioning:** Plans to capitalize on favorable trends in the Indian CDMO space, such as the "China Plus One" strategy.

### Innovation Initiatives and R&D Effectiveness

*   **Initiative:** Modernization of R&D facility, with a new campus at Genome Valley.
*   **Initiative:** Prioritizes chemistry capabilities and niche chemistry.
*   **Effectiveness:** Faster turnaround of RFQs due to digitalization.
*   **Effectiveness:** Strengthening of process safety and Engineering division.
*   **R&D Spend:** FY24: ₹1,612 lakhs (1.57% of total turnover), up from ₹859 lakhs (0.6% of total turnover) in FY23.

### M&A Strategy and Execution

*   **Strategy:** Merger with Cohance Lifesciences to expand capabilities and market reach.
*   **Progress:** Merger with Cohance Lifesciences is in progress, awaiting SEBI and NCLT approvals (expected timeline 12-15 months from February 29, 2024).
*   **Strategy:** Plan to acquire Sapala Organics.
*   **Execution:** Expanding via M&A and is making progress with regulatory approval.

### Management's Track Record in Execution

*   **Execution:** Successfully cleared USFDA audit with zero observations for the Pashamylaram facility.
*   **Execution:** Implemented cost optimization initiatives.
*   **Execution:** New management appointed with new strategies.
*   **Execution:** Inaugurated state-of-the-art R&D Facility.
*   **Execution:** Change in management control pursuant to SEBI SAST Regulations.

### Capital Allocation Strategy

*   **Strategy:** The company retained the entire profit for FY23-24 in retained earnings, and the Board does not recommend paying a dividend.
*   **Strategy:** Focus on CAPEX, evidenced by the completion of an FDA audit and other regulatory audits at the Pashamylaram facility, as well as the inauguration of a new R&D facility.
*   **Strategy:** Investment in working capital as inventory turnover days has been reduced.
*   **Strategy:** Reduction of debt, shown by a decrease in the debt-to-equity ratio.

### Organizational Changes and Their Impact

*   **Change:** The founder promoters sold a 50.10% stake to Berhyanda Limited (Advent International) on September 29, 2023, resulting in a change of management control.
*   **Change:** Significant turnover in Board of Directors and Key Managerial Personnel.
*   **Impact:** Reconstitution of board committees. New management is implementing a new strategic roadmap, focusing on customer engagement, cost optimization, and infrastructure upgrades.
*   **Change:** Creation of new Strategic Business Unit for Specialty Chemicals CDMO.
*   **Impact:** Aim is to better allign with customer expectations and business needs.

## ESG Framework

### Environmental Metrics and Targets

*   Implemented energy conservation measures (auto On/Off switches for cooling towers, flash steam recovery system, LED lighting). Invested approximately ₹ 1 Crore.
*   Utilizing alternate energy sources: 3.05 MWp solar plant and biomass co-firing trials.
*   Pashamylaram Unit 3 site awarded the EHS Excellence Award by the CII.
*   Pashamylaram facility received the International Safety Award from the British Safety Council.

### Social Responsibility Programs

*   Spent ₹ 778.12 lakhs on social and environmental commitments in 2023-24.
*   Key CSR areas: education, healthcare, women empowerment, environmental sustainability, rural development, safe drinking water, and mid-day meal programs.
*   Supported education with books, uniforms, and fee assistance for underprivileged students, partnering for programs like 'Science on Wheels.'
*   Contributed to the Roti Foundation for hunger management by donating over 37,500 meals, benefiting over 3,000 beneficiaries.
*   Setup drinking water facilities in various villages.

### Governance Structure and Effectiveness

*   Board of Directors: 50% Independent Directors, including one Woman Independent Director.
*   Board committees: Audit, Nomination and Remuneration, Stakeholders' Relationship, Risk Management, and Corporate Social Responsibility (all committees have new members effective 29th September 2023).
*   Audit Committee composed of independent and non-executive directors.
*   Whistle Blower Policy in place.
*   Performance evaluation of the Board, its committees, and individual directors conducted as per the Companies Act, 2013 and SEBI (LODR) Regulations, 2015.

### Regulatory Compliance and Future Preparations

*   Pashamylaram facility cleared a USFDA audit with zero 483 observations; New block in Suryapet undergoing validations.
*   Maintains internal financial controls and has a risk management framework.
*   Complies with provisions related to the Internal Complaints Committee under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013. No cases reported during the year.
*   Maintaining Cost Records as prescribed under the law.
*   Ensuring compliance of downstream investments in accordance with the Foreign Exchange Management (Non-debt Instruments) Rules,2019.



{{< rawhtml >}}

<div class="button-container">    
    <a href="https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fec80c4b-d2f3-496a-9e3b-d263ba26c9f7.pdf" target="_blank" class="report-button">
      <i class="fas fa-file-pdf"></i> Download Annual Report
    </a>
</div>
    
{{< /rawhtml >}}
